These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12615436)

  • 1. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice.
    van der Lubben IM; Kersten G; Fretz MM; Beuvery C; Coos Verhoef J; Junginger HE
    Vaccine; 2003 Mar; 21(13-14):1400-8. PubMed ID: 12615436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
    McNeela EA; O'Connor D; Jabbal-Gill I; Illum L; Davis SS; Pizza M; Peppoloni S; Rappuoli R; Mills KH
    Vaccine; 2000 Dec; 19(9-10):1188-98. PubMed ID: 11137256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
    Yasuda Y; Isaka M; Taniguchi T; Zhao Y; Matano K; Matsui H; Morokuma K; Maeyama J; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Jun; 21(21-22):2954-63. PubMed ID: 12798639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid.
    Westerink MA; Smithson SL; Srivastava N; Blonder J; Coeshott C; Rosenthal GJ
    Vaccine; 2001 Dec; 20(5-6):711-23. PubMed ID: 11738734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Matano K; Maeyama J; Komiya T; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 1999 Nov; 18(7-8):743-51. PubMed ID: 10547435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant.
    Rydell N; Sjöholm I
    Vaccine; 2004 Mar; 22(9-10):1265-74. PubMed ID: 15003656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitosan microparticles as oral delivery system for tetanus toxoid.
    Ahire VJ; Sawant KK; Doshi JB; Ravetkar SD
    Drug Dev Ind Pharm; 2007 Oct; 33(10):1112-24. PubMed ID: 17852363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.
    Mills KH; Cosgrove C; McNeela EA; Sexton A; Giemza R; Jabbal-Gill I; Church A; Lin W; Illum L; Podda A; Rappuoli R; Pizza M; Griffin GE; Lewis DJ
    Infect Immun; 2003 Feb; 71(2):726-32. PubMed ID: 12540551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice.
    Jabbal-Gill I; Fisher AN; Rappuoli R; Davis SS; Illum L
    Vaccine; 1998 Dec; 16(20):2039-46. PubMed ID: 9796062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine.
    Aguila A; Donachie AM; Peyre M; McSharry CP; Sesardic D; Mowat AM
    Vaccine; 2006 Jun; 24(24):5201-10. PubMed ID: 16650917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin.
    Ohmura M; Yamamoto M; Kiyono H; Fujihashi K; Takeda Y; McGhee JR
    Vaccine; 2001 Dec; 20(5-6):756-62. PubMed ID: 11738739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan for mucosal vaccination.
    van der Lubben IM; Verhoef JC; Borchard G; Junginger HE
    Adv Drug Deliv Rev; 2001 Nov; 52(2):139-44. PubMed ID: 11718937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chitosan as a novel nasal delivery system for vaccines.
    Illum L; Jabbal-Gill I; Hinchcliffe M; Fisher AN; Davis SS
    Adv Drug Deliv Rev; 2001 Sep; 51(1-3):81-96. PubMed ID: 11516781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pluronic F127-based systemic vaccine delivery systems.
    Coeshott CM; Smithson SL; Verderber E; Samaniego A; Blonder JM; Rosenthal GJ; Westerink MA
    Vaccine; 2004 Jun; 22(19):2396-405. PubMed ID: 15193401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alginate coated chitosan microparticles mediated oral delivery of diphtheria toxoid. Part A. Systematic optimization, development and characterization.
    Shukla A; Mishra V; Bhoop BS; Katare OP
    Int J Pharm; 2015 Nov; 495(1):220-233. PubMed ID: 26319633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations.
    Bal SM; Ding Z; Kersten GF; Jiskoot W; Bouwstra JA
    Pharm Res; 2010 Sep; 27(9):1837-47. PubMed ID: 20559701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs.
    Amidi M; Pellikaan HC; Hirschberg H; de Boer AH; Crommelin DJ; Hennink WE; Kersten G; Jiskoot W
    Vaccine; 2007 Sep; 25(37-38):6818-29. PubMed ID: 17692440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines.
    Baudner BC; Giuliani MM; Verhoef JC; Rappuoli R; Junginger HE; Giudice GD
    Vaccine; 2003 Sep; 21(25-26):3837-44. PubMed ID: 12922117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of chitin and chitosan derivatives in the pharmaceutical field.
    Kato Y; Onishi H; Machida Y
    Curr Pharm Biotechnol; 2003 Oct; 4(5):303-9. PubMed ID: 14529420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.